Skip to content
2000
Volume 18, Issue 3
  • ISSN: 1574-8871
  • E-ISSN: 1876-1038

Abstract

The implementation of the new European Clinical Trial Regulation on 31 January 2022, is a major step to promote clinical research in Europe. The French National Agency for Medicines and Health Products Safety (ANSM) proposes to share some key aspects of the preparation for the application of the Regulation initiated in 2017 and to discuss shared indicators that should be considered to monitor clinical trials opportunities on a territory with regards to access to innovation for patients and attractiveness for sponsors. New criteria based on the time from the first request for authorisation to the first inclusion could be of particular interest to appraise the implementation of the European Clinical Trial Regulation.

Loading

Article metrics loading...

/content/journals/rrct/10.2174/1574887118666230320124012
2023-08-01
2025-10-20
Loading full text...

Full text loading...

/content/journals/rrct/10.2174/1574887118666230320124012
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test